NASDAQ:BIOL - BIOLASE Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.25 -0.06 (-4.58 %)
(As of 01/24/2019 08:14 AM ET)
Previous Close$1.31
Today's Range$1.25 - $1.3364
52-Week Range$0.91 - $2.98
Volume14,740 shs
Average Volume19,827 shs
Market Capitalization$25.83 million
P/E RatioN/A
Dividend YieldN/A
Beta1.48
BIOLASE, Inc., a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the United States and internationally. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems, which are used to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of dental procedures, such as cosmetic, restorative, and complex surgical applications. The company also markets, sells, and distributes dental imaging equipment, including three-dimensional (3D) CAD/CAM intra-oral scanners and digital dentistry software. Its dental imaging products comprise 3Shape Trios intraoral scanners, digital impression systems, and software for taking 3D scans, which are used to design crowns, study models, surgical guides for implant placement, and event orthodontic and athletic appliances. In addition, the company manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces. It sells its products primarily to dentists in general practice through its field sales force and distributor network. BIOLASE, Inc. was founded in 1984 and is headquartered in Irvine, California.

Receive BIOL News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Dental equipment & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BIOL
Previous SymbolNASDAQ:BLTI
CUSIPN/A
Phone949-361-1200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$46.93 million
Book Value$1.43 per share

Profitability

Net Income$-16,850,000.00

Miscellaneous

Employees195
Market Cap$25.83 million
OptionableNot Optionable

BIOLASE (NASDAQ:BIOL) Frequently Asked Questions

What is BIOLASE's stock symbol?

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

When did BIOLASE's stock split? How did BIOLASE's stock split work?

BIOLASE shares reverse split on Friday, May 11th 2018. The 1-5 reverse split was announced on Thursday, May 10th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 10th 2018. An investor that had 100 shares of BIOLASE stock prior to the reverse split would have 20 shares after the split.

How were BIOLASE's earnings last quarter?

BIOLASE Inc (NASDAQ:BIOL) issued its earnings results on Tuesday, November, 13th. The medical technology company reported ($0.19) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.19). The medical technology company earned $10.94 million during the quarter. BIOLASE had a negative return on equity of 76.74% and a negative net margin of 40.31%. View BIOLASE's Earnings History.

When is BIOLASE's next earnings date?

BIOLASE is scheduled to release their next quarterly earnings announcement on Wednesday, March 13th 2019. View Earnings Estimates for BIOLASE.

Has BIOLASE been receiving favorable news coverage?

Media headlines about BIOL stock have trended negative on Thursday, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BIOLASE earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave press coverage about the medical technology company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the stock's share price in the immediate future.

Who are some of BIOLASE's key competitors?

Who are BIOLASE's key executives?

BIOLASE's management team includes the folowing people:
  • Mr. Todd A. Norbe, Pres, CEO & Director (Age 52)
  • Mr. John R. Beaver, Exec. VP & CFO (Age 58)
  • Mr. Richard R. Whipp, VP of Operations (Age 67)
  • Mr. William E. Brown Jr., VP of Bus. Devel. (Age 71)
  • Mr. Daniel Merkin, National Sales Director (Age 46)

How do I buy shares of BIOLASE?

Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BIOLASE's stock price today?

One share of BIOL stock can currently be purchased for approximately $1.25.

How big of a company is BIOLASE?

BIOLASE has a market capitalization of $25.83 million and generates $46.93 million in revenue each year. BIOLASE employs 195 workers across the globe.

What is BIOLASE's official website?

The official website for BIOLASE is http://www.biolase.com.

How can I contact BIOLASE?

BIOLASE's mailing address is 4 CROMWELL, IRVINE CA, 92618. The medical technology company can be reached via phone at 949-361-1200 or via email at [email protected]


MarketBeat Community Rating for BIOLASE (NASDAQ BIOL)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  190 (Vote Outperform)
Underperform Votes:  181 (Vote Underperform)
Total Votes:  371
MarketBeat's community ratings are surveys of what our community members think about BIOLASE and other stocks. Vote "Outperform" if you believe BIOL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/24/2019 by MarketBeat.com Staff

Featured Article: Net Income

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel